Date Main Theme / Chairman
1st (1994) Current situation of human biomaterials' usage in Japan, US and EU

2nd (1995) Challenge to the use of human biomaterials in Japan

3rd (1996) Problems of in vitro use of human liver materials

4th (1997) Advantage and disadvantage of drug metabolism studies using human liver slices

5th (1998) Prediction of metabolism and toxicity of drugs
　Hajime Yasuhara, M.D., Ph.D. (Showa University)
6th (1999) Present and future perspectives of human biomaterial usage
　Masahiro Hayashi, Ph.D. (Tokyo University of Science)
7th (2000) Progress of human biomaterial usage in the medical sciences and improvement in the social environment
　Tetsuya Suga, Ph.D. (Tokyo University of Pharmacy and Life Sciences)
8th (2001) Use of human biomaterial in drug development: Pharmacokinetics, efficacy, toxicity, individual difference and drug-drug interactions
　Yuichi Sugiyama, Ph.D. (University of Tokyo)
9th (2002) Use of human biomaterials in the development and safety assessment of drug, pesticides and food additives
　Takemi Yoshida, Ph.D. (Showa University)
10th (2003) Usefulness and ethical problem in the use of human biomaterials in medical science
　Shinnichi Kobayashi, M.D., Ph.D. (St. Marianna University)
11st (2004) Usage of human biomaterials in the state-of-the-art medical science
　Yasuo Ohno, Ph.D. (National Institute of Health Sciences)
12nd (2005) Usage of human biomaterials in the effectiveness and safety assessment of new drugs
　Toshihiko Ikeda, Ph.D. (Sankyo Co., LTD.)
13rd (2006) Improvement of usage of human biomaterials in the progress of drug development
　Kitaro Oka, Ph.D. (Tokyo University of Pharmacy and Life Sciences)
14th (2007) Usage of human biomaterials in advanced medical technology to improve medical care
　Mituo Kusano, M.D., Ph.D. (Showa University)
15th (2008) Future progress of drug development and medical care using human biomaterials
　Toshio Suwa, Ph.D. (Kyoritu College of Pharmacy)
16th (2009) Usefulness of human biomaterials in drug development and drug treatment in individuals -Promotion for human biomaterials' application to drug discovery/development in support of medical cares-
　Mitukazu Kitada, Ph.D. (Chiba University Hospital)
17th (2010) Challenge to prediction of effectiveness and toxicity of drugs using human biomaterials based on cell technology-
　Ikuo Horii, Ph.D. (Pfizer Co., LTD.)
18th (2011) Desirable correlation of pharmacokinetics/toxicity studies and clinical trials in drug development
　Yasushi Yamazoe, Ph.D. (Tohoku University)
19th (2012) Progress of exploratory IND studies and translational research to promote new drug development in Japan
　Takashi Izumi, Ph.D. (Daiichi Sankyo Co., LTD.)
20th (2013) Industry-Academia-Government Collaboration Required for Drug Development and Life Science Innovation
　Satoshi Toyoshima, Ph.D. (Japan Pharmacists Education Center)
21st (2014) Strategies for New Drug Development using Innovative Technologies
　Toshiya Moriwaki, Ph.D. (Takeda Pharmaceutical Co., Ltd.)
22nd (2015) Strategic infrastructure maintenance to develop revolutionary new drugs
　Shigeru Omori, Ph.D. (Shinshu University Hospital)
23rd (2016) Multifaceted Study of the Hepatotoxicity
　Akiyoshi Suganuma, D.V.M., Ph.D. (Eisai Co., Ltd.)
24th (2017) Expectation for use of modeling in drug development and medical care
　Akihiro Hisaka, Ph.D. (Chiba University)